Articles Posted in Pharmaceutical Litigation

Published on:

Abbott Laboratories will withdraw its diet pill Meridia in the U.S. and Canada, after coming under pressure because the drug increases the risk of heart attack and stroke.

FDA scientists requested the withdrawal because Meridia’s risks were not outweighed by any real benefit.

European regulators pulled the product off the market in January after a study showed that patients with heart disease had an 11 percent chance of heart attacks or stroke while taking the drug compared with a 10 percent risk for those not taking it.

Published on:

The U.S. Supreme Court rejected a drug company’s appeal to block an Arkansas defective drug trial to assess punitive damages. The Court also let stand a compensatory damage award for 2.75 million in the case of a woman who got breast cancer after taking hormone replacement therapy.

The Plaintiff alleged that the drug company did not provide adequate warning regarding the risk of the drugs. The Plaintiff will now proceed to trial to determine whether punitive damages should be awarded. The trial will take place in Federal District Court in Little Rock.

Little Rock, Arkansas personal injury lawyer Paul Pfeifer has successfully litigated personal injury cases in Arkansas State and Federal Courts. If you have a case involving a personal injury call the Pfeifer Law Firm to discuss your legal rights.

Published on:

The U.S. Supreme Court gave a victory to patient lawsuits against drugmakers, upholding a $7 million award to a woman who lost her arm after being injected with Wyeth’s Phenergan nausea treatment. The Court, in Wyeth v. Levine, voting 6-3, said patients can use state product liability statutes to bring a case that involves companies failing to provide adequate safety warnings for dangerous drugs. In this case, pharmaceutical makers argued that they were shielded from lawsuits by the Food and Drug Administration’s approval of a treatment and its packaging information. However, the U.S. Supreme Court disagreed.

“Congress did not intend FDA oversight to be the exclusive means of ensuring drug safety and effectiveness,” Justice John Paul Stevens wrote for the court.

The ruling is a defeat for drug companies in a case that might have given them a shield from product liability suits in Arkansas and all other states. Justices Anthony Kennedy, David Souter, Stephen Breyer, Ruth Bader Ginsburg and Clarence Thomas joined Stevens in the majority.